Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa

INTRODUCTION: resistance to sulfadoxine-pyrimethamine (SP) across Africa, from 2000 to 2020. METHODS: We assembled molecular, clinical and endemicity data covering malaria-endemic African countries up to December 2018. Subsequently, we reconstructed georeferenced patient data, using pfdhps540E and pfdhps581G to measure mid-level and high-level SP resistance. Gaussian process regression was applied to model spatiotemporal standardised prevalence. RESULTS: In eastern Africa, mid-level SP resistance increased by 64.0% (95% uncertainty interval, 30.7%-69.8%) in Tanzania, 55.4% (31.3%-65.2%) in Sudan, 45.7% (16.8%-54.3%) in Mozambique, 29.7% (10.0%-45.2%) in Kenya and 8.7% (1.4%-36.8%) in Malawi from 2000 to 2010. This was followed by a steady decline of 76.0% (39.6%-92.6%) in Sudan, 65.7% (25.5%-85.6%) in Kenya and 17.4% (2.6%-37.5%) in Tanzania from 2010 to 2020. In central Africa, the levels increased by 28.9% (7.2%-62.5%) in Equatorial Guinea and 85.3% (54.0%-95.9%) in the Congo from 2000 to 2020, while in the other countries remained largely unchanged. In western Africa, the levels have remained low from 2000 to 2020, except for Nigeria, with a reduction of 14.4% (0.7%-67.5%) and Mali, with an increase of 7.0% (0.8%-25.6%). High-level SP resistance increased by 5.5% (1.0%-20.0%) in Malawi, 4.7% (0.5%-25.4%) in Kenya and 2.0% (0.1%-39.2%) in Tanzania, from 2000 to 2020. CONCLUSION: Under the WHO protocols, SP is no longer effective for intermittent preventive treatment in pregnancy and infancy in most of eastern Africa and parts of central Africa. Strengthening health systems capacity to monitor drug resistance at subnational levels across the endemicity spectrum is critical to achieve the global target to end the epidemic

Biology · Drug resistance · Geography · Malaria · Plasmodium falciparum · Pyrimethamine · Sulfadoxine · Sulfadoxine/pyrimethamine · Tanzania · Veterinary medicine · Demography · Malaria Research and Control · Medicine · Mosquito-borne diseases and control · Trypanosoma species research and implications · Immunology

• “I want to help my body”

  Open Access•Sarah Svege, Siri Lange et al.•PLOS Global Public Health•2025

  Incluir item

• A review of prospective pathways and impacts of Covid-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa

  Open Access•Floriano Amimo, Bernd Lambert et al.•Globalization and Health•2021

  Incluir item

• Global, regional, and national disability-adjusted life-years (Dalys) for 359 diseases and injuries and healthy life expectancy (Hale) for 195 countries and territories, 1990–2017

  Open Access•Hmwe Hmwe Kyu, D Abate et al.•The Lancet•2018

  Incluir item

• The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015

  Open Access•Samir Bhatt, D J Weiss et al.•Nature•2015

  Incluir item

• Guidelines for Accurate and Transparent Health Estimates Reporting

  Open Access•G A Stevens, Leontine Alkema et al.•The Lancet•2016

  Incluir item

• Global, regional, and national disability-adjusted life-years (Dalys) for 333 diseases and injuries and healthy life expectancy (Hale) for 195 countries and territories, 1990–2016

  Open Access•Simon I Hay, Amanuel Alemu Abajobir et al.•The Lancet•2017

  Incluir item